Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06025578 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

A Phase 3 study of Progressive Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
1,092
Enrollment target
20
Study locations

NCT06025578 is a Phase 3 study of Progressive Pulmonary Fibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,092 participants, above the 549-participant average among 7 other Progressive Pulmonary Fibrosis trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06025578, a Phase 3 study of Progressive Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,092 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Conditions Studied

Progressive Pulmonary Fibrosis

Interventions

  • DRUG BMS-986278
  • DRUG BMS-986278 Placebo

Study Locations (20)

California

  • Local Institution - 0336 - La Jolla
  • Local Institution - 0212 - Los Angeles
  • Local Institution - 0019 - Los Angeles
  • Local Institution - 0535 - Newport Beach
  • Local Institution - 0366 - Orange
  • Local Institution - 0341 - Sacramento
  • Local Institution - 0015 - San Francisco
  • Local Institution - 0352 - Stanford

Florida

  • Local Institution - 0195 - Brandon
  • Local Institution - 0380 - Celebration
  • Local Institution - 0013 - Clearwater
  • Local Institution - 0396 - DeBary

Colorado

  • Local Institution - 0321 - Aurora
  • Local Institution - 0376 - Denver

Connecticut

  • Local Institution - 0211 - New Haven
  • Local Institution - 0418 - Stamford

Alabama

  • Local Institution - 0046 - Birmingham

Arizona

  • Local Institution - 0314 - Phoenix

Delaware

  • Local Institution - 0067 - Newark

District of Columbia

  • Local Institution - 0354 - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,092 participants
Start Date 2023-10-25
Est. Completion 2027-12-27
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06025578

The ClinicalTrials.gov registry entry for NCT06025578 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,092 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 549-participant average among 7 other Progressive Pulmonary Fibrosis trials with a reported enrollment target (99% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Progressive Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986278 is the first listed.

NCT06025578 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT06025578 about?

NCT06025578 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

What is the current status of trial NCT06025578?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,092 participants. The study started on 2023-10-25. Estimated completion is 2027-12-27.

What conditions does trial NCT06025578 study?

This clinical trial studies the following conditions: Progressive Pulmonary Fibrosis.

What interventions are being tested in trial NCT06025578?

The interventions under investigation include: BMS-986278 (DRUG), BMS-986278 Placebo (DRUG).

Who is sponsoring clinical trial NCT06025578?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06025578 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Progressive Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Progressive Pulmonary Fibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.